Eurobio Scientific Faces Mandatory Buyout Offer Filing
A mandatory squeeze-out tender offer targeting Eurobio Scientific shares was filed Sept. 24, 2026, signaling a full delisting push.
A withdrawal offer followed by a mandatory squeeze-out procedure targeting the shares of Eurobio Scientific was filed on September 24, 2026, according to a regulatory communiqué released by the French diagnostics company. The move marks a significant step toward removing Eurobio Scientific from public trading.
Such procedures, known in French securities law as an *offre publique de retrait* followed by a *retrait obligatoire*, allow a majority shareholder that controls a sufficiently large stake to compel remaining minority shareholders to sell their holdings at a set price. The mechanism is designed to give minority investors a defined exit while enabling the controlling party to consolidate full ownership.
Read more ARK Investment Management Issues Correction to ARKY Fund Announcement →
The September 24 filing represents the formal regulatory trigger point in this process. Under French market rules, once the offer is validated by regulators and the conditions are met, minority shareholders are required to tender their shares, effectively ending Eurobio Scientific's status as a publicly traded entity.
The announcement was communicated through GlobeNewswire in the financial services sector, suggesting the company is moving through the procedural stages that typically precede a final delisting from the stock exchange. No additional financial terms or acquiring-party details were disclosed in the source communiqué beyond the filing date and nature of the offer.
Continue reading at GlobeNewswire - Industry News on Financial Services.
